Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults.
The response to an inactivated hepatitis A vaccine was assessed in 307 persons: 163 Alaska Native children, ages 3-6 years, and 144 Native (84) and non-Native (60) adults. All adults received the same vaccine schedule (0, 1, and 12 months), whereas children were randomized to receive three different schedules (0, 1, and 6; 0, 1, and 2; or 0, 1, and 12 months). After one dose, 141 (96%) of 147 children and 129 (90%) of 143 adults responded with levels of antibody to hepatitis A virus > 20 mIU/mL. After three doses, all participants responded. The geometric mean titer (GMT) 1 month after the third dose was significantly higher in children who received the third dose 12 months after the first dose rather than 2 months after the first dose. While there were differences in the GMT of some blood samples by age, sex, and ethnicity, all participants responded to the vaccine.
McMahon
B J
BJ
Alaska Native Medical Center, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage 99501.
Williams
J
J
Bulkow
L
L
Snowball
M
M
Wainwright
R
R
Kennedy
M
M
Krause
D
D
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000413:Alaska; D002675:Child, Preschool; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies / Q000097:blood; D006507:Hepatovirus / Q000276:immunology*; D006801:Humans; D007198:Indians, North American; D012737:Sex Factors; D015164:Vaccines, Inactivated / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines